Bernard A. Fox, Co – founder, President, and CEO of UbiVac, shared Patrick Hwu’s, President and CEO at Moffitt Cancer Center, post on LinkedIn:
“Great being interviewed by the Amazing Prof. Patrick Hwu . Appreciated chance to talk about what I know to be the Hottest topic in Cancer Immunotherapy!
Cancer’s Dark Matter!
Newly discovered!
Shared by Cancers
Some support Malignant Properties and may be Cancer Drivers
This is reviewed in this weeks Journal for ImmunoTherapy of Cancer – April 2nd, 2026.
An National Cancer Institute (NCI) SBIR funded development and a small phase I/II trial of UbiVac ‘s DPV001 as adjuvant treatment for NSCLC. Now we know DPV-001 contains >400 of these Dark Matter antigens.
In a phase Ib combo immunotherapy trial led by Dr. Rom Leidner and funded by Incyte , for pts with recurrent/metastatic HNSCC, UbiVac ‘s DPV001, has tripled response rates , tripled PFS, and doubled OS.
In 1st line pts we have a 56% RR.
In PD-1 refractory patients, a group that represents one of the largest groups of patients in need of options, we have a 33% RR.”
Quoting Patrick Hwu’s post:
“CYMI: The latest episode of The ImmunoVerse features Dr. Bernard Fox of Chiles Research Providence.
We dive into the “dark matter” of our DNA and how it could reveal new paths for immunotherapy, from cancer vaccines to TCR-based approaches.
Plus, a look back at the early days at the National Cancer Institute (NCI) and why mentorship still matters.
Check it out at Moffitt.org/ImmunoVerse or listen on all major podcast platforms!”
Other articles featuring Bernard A. Fox and Patrick Hwu on OncoDaily.